Significant strides made in Nxera Pharma's oral compound for neurological conditions 09-May-2024 By Liza Laws Neurocrine Biosciences Inc. has initiated its phase 1 clinical study, marking a significant stride in the evaluation of NBI-1117567, an investigational small molecule, oral compound developed by Nxera Pharma.
AxoSim's acquisition of microBrain to transform neurological R&D 24-Oct-2023 By Liza Laws A company’s goal of delivering human data faster to ‘transform neurological R&D’ has been boosted by the completion of an acquisition.
Evotec and BMS sign eight-year neuro discovery deal 03-Apr-2023 By Ben Hargreaves The two companies extend their ongoing partnership by a further eight years to discover treatments for neurodegenerative conditions.